Top 5 Most-Read Psoriasis Content of 2023

The most-read psoriasis articles this year on AJMC.com included topics on new therapies and biologics for the treatment of psoriasis in adult patients.

These are the most-viewed psoriasis articles of 2023.

5. Wildfire Air Pollution Linked With Increased Rates of Psoriasis Clinic Visits Among Adults

Air pollution from wildfires was linked to increased rates of clinic visits for psoriasis in adults over time, according to one study. The study focused on the impact of the California Camp Fire on air quality in San Francisco, revealing a significant rise in psoriasis clinic visits among adults at a 5-week lag, peaking at 8 and 9 weeks after the fire. The findings highlight the potential environmental triggers for psoriasis flares and emphasize the need for further research in locations with wildfires to understand the broader impact on health care systems.

Read the article here.

4. Drugs Affecting the IL-23 Pathway May Lower Risk of Psoriatic, Inflammatory Arthritis From Psoriasis

A study suggests that treatment with IL-12/23 or IL-23 inhibitors is associated with a lower risk of progression to inflammatory arthritis in patients with psoriasis compared with tumor necrosis factor inhibitors. The study, based on data from a national sample of patients in the United States, revealed a significantly lower risk of developing inflammatory arthritis in patients prescribed IL-12/23 inhibitors or IL-23 inhibitors, highlighting the potential benefits of these treatments in preventing the progression from psoriasis to psoriatic arthritis. The researchers recommend further research using prospective observational cohorts and pooled analyses of randomized trials to confirm these findings.

Read the article here.

3. FDA Delays UCB’s Bimekizumab Approval

In late September, UCB received a positive Establishment Inspection Report from the FDA following a prelicense inspection at its Belgium manufacturing facility for the production of bimekizumab (Bimzelx) to treat adults with moderate to severe plaque psoriasis. Weeks later, the FDA approved the drug, and it has since launched on the market, making it the first dual IL-17A and IL-17F inhibitor to treat the condition.

Read the article here.

2. Biologics May Prevent PsA in Patients With Psoriasis

Research presented at the American Academy of Dermatology annual meeting suggested that the use of biologics may reduce the development of psoriatic arthritis (PsA) among patients with psoriasis. The retrospective cohort study, which utilized data from 2007 to 2021, found that patients treated with biologics had a lower incidence of PsA after 10 years compared with those treated with phototherapy only. The study adds to the ongoing exploration of the role of biologics in preventing the development of PsA in individuals with psoriasis.

Read the article here.

1. Migraine More Common in Patients With Psoriasis, Say Findings

A case-control study in Iran found that patients with psoriasis face a significantly higher risk of migraine, particularly migraine with aura, compared with individuals without psoriasis. The study showed that 21.2% of patients with psoriasis had migraine, compared with 8.7% of age- and gender-matched controls. The risk of migraine was more prominent in patients with worse psoriasis severity and was highest in those with PsA, suggesting a potential connection between chronic systemic inflammation and the development of both conditions.

Read the article here.